8月13日，翰森制药盘中上涨3.94%，报34.8港元/股，成交额1.51亿港元。制药板块今日整体回暖，石药集团涨5.88%，长风药业涨5.15%，恒瑞医药涨1.61%，中国生物制药涨1.52%。
消息面上，公司近期利好密集。核心品种HS-20093先后在小细胞肺癌及骨肉瘤两项III期关键性临床试验中达到主要终点，公司正推进上市申报；8月6日新药HS-10582片获NMPA临床试验批准，拓展心血管代谢管线。里昂维持"跑赢大市"评级并将目标价升至42港元，预计明年将有5款新药获批上市。公司中期业绩将于8月26日披露，市场对业绩兑现预期升温。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.